Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.780
+0.130 (3.56%)
At close: Jun 26, 2026, 4:00 PM EDT
3.850
+0.070 (1.85%)
After-hours: Jun 26, 2026, 7:34 PM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$2,368,091
Market Cap
292.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Bicycle Therapeutics | 288 |
| Entrada Therapeutics | 152 |
| Zentalis Pharmaceuticals | 106 |
| Neumora Therapeutics | 92 |
| SAB Biotherapeutics | 86 |
| InflaRx | 65 |
| Immuneering | 55 |
ELDN News
- 2 days ago - Natera, Eledon announce strategic partnership - TheFly
- 2 days ago - Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Business Wire
- 5 days ago - Eledon Pharmaceuticals Transcript: Study result - Transcripts
- 5 days ago - Eledon Pharmaceuticals Press release: Study result - Filings
- 5 days ago - Eledon Pharmaceuticals Slides: Study result - Filings
- 5 days ago - Eledon Pharmaceuticals announces new long-term data from BESTOW program - TheFly
- 5 days ago - Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus - GlobeNewsWire
- 19 days ago - Eledon Pharmaceuticals announces updated results from tegoprubart trial - TheFly